Cosmo Pharma stock drops 16% after €175m CB surprises funds

Shares in Cosmo Pharmaceuticals, the Swiss-listed maker of gastro-intestinal drugs, plummeted by 16% on Thursday after it had launched a €175m convertible bond on Wednesday evening, after market close.

  • By Sam Kerr
  • 29 Nov 2018

Berenberg, Credit Suisse and Jefferies were bookrunners.

They launched the €175m five year deal with an increase option of €25m, at a coupon range of 1.75% to 2.5%. The conversion price was a fixed offer, at €122.7, the euro equivalent of a 20% premium to the reference price of ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 JPMorgan 161,597.45 701 8.06%
2 Citi 158,100.45 638 7.89%
3 Bank of America Merrill Lynch 131,322.73 520 6.55%
4 Barclays 126,396.71 489 6.30%
5 HSBC 104,257.54 522 5.20%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Bank of America Merrill Lynch 12,900.23 34 6.65%
2 BNP Paribas 12,334.48 61 6.36%
3 UniCredit 11,196.47 58 5.77%
4 Citi 9,580.75 37 4.94%
5 Deutsche Bank 8,953.95 35 4.62%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Morgan Stanley 5,454.13 25 10.64%
2 JPMorgan 4,766.13 27 9.30%
3 Goldman Sachs 4,280.20 20 8.35%
4 Citi 3,649.88 23 7.12%
5 UBS 3,602.23 16 7.03%